

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2011; month=8; day=24; hr=10; min=25; sec=47; ms=770;]

=====

Reviewer Comments:

<120> Method for Preparation and Purification of Recombinant Proteins

Please insert the following mandatory lines below the "<120>" line:

<130>

Please insert the "<130>" and its mandatory response. "<130>" represents the file reference; the attorney docket number is the usual response.

<140> US 10/593,315 (current application number)

<141> 2006-09-18 (filing date)

Please also insert the above mandatory current application data lines.

To correct the sequence listing errors noted in this report - The recommended method for correction of errors is to access the sequence listing working file using the software program in which the listing was originally prepared, e.g., the project file in PatentIn, make any necessary corrections within that program, then generate a new sequence listing file. Use of a word processing program to correct errors directly in the original sequence listing file is strongly discouraged, since such programs often introduce unintended changes to the sequence listing, rendering the listing unacceptable. When the working file or original program is not available for correction, then use of a common or plain text-only editor, such as NotePad, to edit the original sequence listing file may suffice.

Application No: 10593315 Version No: 1.0

Input Set:

Output Set:

Started: 2011-08-16 16:36:54.869
Finished: 2011-08-16 16:36:55.086
Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 217 ms
Total Warnings: 3
Total Errors: 0
No. of SeqIDs Defined: 3
Actual SeqID Count: 3

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)

Sequence Listing

<110> Nexgen Biotechnologies, INC

<120> Method for Preparation and Purification of Recombinant Proteins

<160> 3

<170> KopatentIn 1.71

<210> 1

<211> 126

<212> DNA

<213> Artificial Sequence

<220>

<223> optimized AFP nucleotide sequence

<400> 1

atggatgctc cagctaaagc agcagcaaaa acagctgcag atgcaaaagc tgctgctgct 60

aaaactgcag cagatgcatt agctgctgct aataaaaactg cagcagctgc taaaggcagct 120

gcaaaa 126

<210> 2

<211> 165

<212> DNA

<213> Artificial Sequence

<220>

<223> AFPN nucleotide sequence comprising AFP nucleotide sequence

<400> 2

ccatggatgc tccagctaaa gcagcagcaa aaacagctgc agatgcaaaa gctgctgctg 60

ctaaaaactgc agcagatgca ttagctgctg ctaataaaac tgcagcagct gctaaaggcag 120

ctgcaaaaaga cgacgacgac aaggctctag aggtccata gatct 165

<210> 3

<211> 171

<212> DNA

<213> Artificial Sequence

<220>

<223> AFPC nucleotide sequence comprising AFP nucleotide sequence

<400> 3

ccatggctct agaggatccc ctcgttccac gaggatctat ggatgctcca gctaaaggcag 60

cagcaaaaac agctgcagat gcaaaagctg ctgctgctaa aactgcagca gatgcattag 120

ctgctgctaa taaaactgca gcagctgcta aagcagctgc aaaatagatc t

171